LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $68.20.

LMAT has been the topic of several research analyst reports. Barrington Research lifted their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. KeyCorp began coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th.

LeMaitre Vascular Stock Up 2.3 %

Shares of LeMaitre Vascular stock opened at $64.23 on Wednesday. The firm has a market cap of $1.44 billion, a PE ratio of 47.93, a P/E/G ratio of 2.73 and a beta of 0.87. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $74.64. The business has a 50-day moving average price of $65.21 and a 200 day moving average price of $57.97.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The business had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $49.01 million. During the same period in the previous year, the business earned $0.25 earnings per share. The business’s revenue was up 19.3% compared to the same quarter last year. On average, sell-side analysts expect that LeMaitre Vascular will post 1.66 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were given a dividend of $0.16 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. The ex-dividend date was Wednesday, March 13th. This represents a $0.64 annualized dividend and a dividend yield of 1.00%. LeMaitre Vascular’s payout ratio is presently 47.76%.

Insider Activity

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now directly owns 5,309 shares in the company, valued at approximately $358,357.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director John A. Roush sold 7,500 shares of LeMaitre Vascular stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at $157,182. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Insiders sold a total of 114,036 shares of company stock valued at $7,873,749 in the last 90 days. Company insiders own 12.40% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Large investors have recently bought and sold shares of the stock. Envestnet Asset Management Inc. grew its position in shares of LeMaitre Vascular by 24.8% during the third quarter. Envestnet Asset Management Inc. now owns 195,983 shares of the medical instruments supplier’s stock worth $10,677,000 after buying an additional 38,958 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of LeMaitre Vascular by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,510,567 shares of the medical instruments supplier’s stock valued at $82,296,000 after purchasing an additional 33,500 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in shares of LeMaitre Vascular by 0.5% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock worth $109,432,000 after purchasing an additional 10,390 shares in the last quarter. Johnson Investment Counsel Inc. increased its holdings in LeMaitre Vascular by 52.6% in the third quarter. Johnson Investment Counsel Inc. now owns 32,745 shares of the medical instruments supplier’s stock valued at $1,784,000 after buying an additional 11,280 shares during the last quarter. Finally, Dark Forest Capital Management LP raised its stake in LeMaitre Vascular by 152.9% in the third quarter. Dark Forest Capital Management LP now owns 13,857 shares of the medical instruments supplier’s stock valued at $755,000 after buying an additional 8,378 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.